BACKGROUND: Although insulin resistance and decreased insulin secretion are characteristics of established type 2 DM, which of these metabolic abnormalities is the primary determinant of type 2 DM is controversial. It is also not well known how insulin resistance and beta cell dysfunction influence serum insulin, proinsulin, proinsulin/insulin ratio in type 2 DM. METHODS: We compared serum insulin, proinsulin and proinsulin/insulin ratio in type 2 diabetic patients and control subjects. We also investigated the relationship between serum insulin, proinsulin and proinsulin/insulin ratio and several biochemical markers which represent insulin resistance or beta cell function. RESULTS: Insulin, proinsulin and proinsulin/insulin ratio were significantly higher in type 2 DM than control(p < 0.001). In diabetic patients, total insulin level was correlated with urinary albumin excretion rates(r = 0.224, p = 0.025) and body mass index(r = 0.269, p = 0.014). Proinsulin level was correlated with fasting C-peptide(r = 0.43, p = 0.002), postprandial 2 hour blood glucose(r = 0.213, p = 0.05) and triglyceride(r = 0.28, p = 0.022). Proinsulin/insulin ratio was positively correlated with fasting C-peptide(r = 0.236, p = 0.031), fasting blood glucose (r = 0.264, p = 0.015), postprandial 2 hour blood glucose(r = 0.277, p = 0.001) and triglyceride(r = 0.428, p < 0.001). In control subjects, insulin level was correlated with triglyceride(r = 0.366, p = 0.002). Proinsulin/insulin ratio was correlated with age(r = 0.241, p = 0.044). CONCLUSION: The serum levels of insulin and proinsulin seem to be associated with several markers of insulin resistance. Whereas proinsulin/insulin ratio might represent beta cell function rather than insulin resistance. But more studies are needed to clarify the mechanisms of elevated proinsulin/insulin ratio in type 2 DM.
BACKGROUND: Although insulin resistance and decreased insulin secretion are characteristics of established type 2 DM, which of these metabolic abnormalities is the primary determinant of type 2 DM is controversial. It is also not well known how insulin resistance and beta cell dysfunction influence serum insulin, proinsulin, proinsulin/insulin ratio in type 2 DM. METHODS: We compared serum insulin, proinsulin and proinsulin/insulin ratio in type 2 diabeticpatients and control subjects. We also investigated the relationship between serum insulin, proinsulin and proinsulin/insulin ratio and several biochemical markers which represent insulin resistance or beta cell function. RESULTS:Insulin, proinsulin and proinsulin/insulin ratio were significantly higher in type 2 DM than control(p < 0.001). In diabeticpatients, total insulin level was correlated with urinary albumin excretion rates(r = 0.224, p = 0.025) and body mass index(r = 0.269, p = 0.014). Proinsulin level was correlated with fasting C-peptide(r = 0.43, p = 0.002), postprandial 2 hour blood glucose(r = 0.213, p = 0.05) and triglyceride(r = 0.28, p = 0.022). Proinsulin/insulin ratio was positively correlated with fasting C-peptide(r = 0.236, p = 0.031), fasting blood glucose (r = 0.264, p = 0.015), postprandial 2 hour blood glucose(r = 0.277, p = 0.001) and triglyceride(r = 0.428, p < 0.001). In control subjects, insulin level was correlated with triglyceride(r = 0.366, p = 0.002). Proinsulin/insulin ratio was correlated with age(r = 0.241, p = 0.044). CONCLUSION: The serum levels of insulin and proinsulin seem to be associated with several markers of insulin resistance. Whereas proinsulin/insulin ratio might represent beta cell function rather than insulin resistance. But more studies are needed to clarify the mechanisms of elevated proinsulin/insulin ratio in type 2 DM.
Authors: M F Saad; S E Kahn; R G Nelson; D J Pettitt; W C Knowler; M W Schwartz; S Kowalyk; P H Bennett; D Porte Journal: J Clin Endocrinol Metab Date: 1990-05 Impact factor: 5.958
Authors: S E Kahn; D L Leonetti; R L Prigeon; E J Boyko; R W Bergstrom; W Y Fujimoto Journal: J Clin Endocrinol Metab Date: 1995-04 Impact factor: 5.958
Authors: D C Robbins; L Andersen; R Bowsher; R Chance; B Dinesen; B Frank; R Gingerich; D Goldstein; H M Widemeyer; S Haffner; C N Hales; L Jarett; K Polonsky; D Porte; J Skyler; G Webb; K Gallagher Journal: Diabetes Date: 1996-02 Impact factor: 9.461
Authors: Sarah R Preis; Joseph M Massaro; Sander J Robins; Udo Hoffmann; Ramachandran S Vasan; Thomas Irlbeck; James B Meigs; Patrice Sutherland; Ralph B D'Agostino; Christopher J O'Donnell; Caroline S Fox Journal: Obesity (Silver Spring) Date: 2010-03-25 Impact factor: 5.002
Authors: Manush Saydmohammed; Anupma Jha; Vineet Mahajan; Dillon Gavlock; Tong Ying Shun; Richard DeBiasio; Daniel Lefever; Xiang Li; Celeste Reese; Erin E Kershaw; Vijay Yechoor; Jaideep Behari; Alejandro Soto-Gutierrez; Larry Vernetti; Andrew Stern; Albert Gough; Mark T Miedel; D Lansing Taylor Journal: Exp Biol Med (Maywood) Date: 2021-05-06
Authors: Sara Sokooti; Wendy A Dam; Tamas Szili-Torok; Jolein Gloerich; Alain J van Gool; Adrian Post; Martin H de Borst; Ron T Gansevoort; Hiddo J L Heerspink; Robin P F Dullaart; Stephan J L Bakker Journal: J Pers Med Date: 2022-07-12